

FOR IMMEDIATE RELEASE

Contact: Karen Michailo
919-287-4277

Expression Analysis Announces Extension of their Preferred Vendor Status for Genomics Services with GlaxoSmithKline

Durham, N.C. (July 25, 2008) – Expression Analysis, Inc., the industry's leading provider of genomic services for clinical trials and research, announced today they have renewed their agreement with GlaxoSmithKline as a Preferred Vendor for genomic services. The company initially entered into the agreement to provide microarray genotyping services back in 2006. Since that time, the scope of services has been extended to include expression profiling, sample preparation as well as other services, as needed.

Steve McPhail, CEO of Expression Analysis said "We are very pleased GSK has been satisfied with the quality of our services and the level of customer service we provide, to extend our Preferred Vendor status and renew our services agreement. We strive every day to provide clients with quality and service that exceeds their expectations."

Dr. Stephanie Chissoe, Sr. Director of Pharmacogenetics at GlaxoSmithKline commented that "Expression Analysis has been a valued partner in providing quality cost effective genomic services and we look forward to our continued partnership."

About Expression Analysis, Inc.

Expression Analysis, Inc. provides expression profiling and genotyping and sequencing services using Illumina Bead-Chip®, Affymetrix GeneChip® and Applied Biosystems' TaqMan technologies. As the leading provider of microarray services in clinical trials and research, Expression Analysis offers solutions for challenging specimens such as blood and FFPE tissues, as well as nucleic acid isolation and data analysis services. The organizations CLIA registered lab supports GLP compliance.

For more information visit www.ExpressionAnalysis.com

— END —